BioPharmSignal logoBioPharmSignal

Biotech News

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Prelude Therapeutics (PRLD)Prelude TherapeuticsFDA / regulatory

Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026. WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S.

Related news

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

COGTCogent Biosciences2026-09-15 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

RVMDRevolution Medicines2026-07-22 20:05 EST

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

RVMDRevolution Medicines2026-09-14 20:05 EST

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

PRLDPrelude Therapeutics2026-08-11 11:00 EST

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

REPLReplimune Group2026-08-06 20:00 EST

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

REPLReplimune Group2026-07-30 22:15 EST

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

View all latest news

Prelude Therapeutics

Precision Oncology Company Prelude Therapeutics develops medicines for validated cancer targets using selective degradation and mutant-specific inhibition. PRT12396 PRT12396 selectively inhibits mutant JAK2V617F and is in Phase 1 development for polycythemia vera and myelofibrosis. PRT13722 PRT13722 is an oral KAT6A degrader intended for...

Recent company news

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PRLDPrelude Therapeutics2026-09-10 11:01 EST

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

PRLDPrelude Therapeutics2026-08-11 11:00 EST

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRLDPrelude Therapeutics2026-05-12 11:01 EST

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

PRLDPrelude Therapeutics2026-04-20 10:30 EST

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Stock data

Close
4.57 USD
Market cap
278.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States